Valuation : Cann Group Limited

Market Cap 8.3M 5.95M 5.13M 4.86M 4.4M 8.26M 569M 57.7M 22.19M 289M 22.36M 21.87M 915M P/E 2024
-0.23x
P/E 2025 -0.24x
Enterprise Value 84.13M 60.34M 51.99M 49.23M 44.62M 83.71M 5.76B 585M 225M 2.93B 227M 222M 9.27B EV / Sales 2024
4.54x
EV / Sales 2025 6.2x
Free-Float
78.02%
Yield 2024 *
-
Yield 2025 -
Current month+25.00%
1 month+42.86%
3 months+25.00%
6 months-33.33%
Current year-44.44%
1 week 0
Extreme 0.004
0.01
1 month 0
Extreme 0.003
0.01
Current year 0
Extreme 0.002
0.01
1 year 0
Extreme 0.002
0.02
3 years 0
Extreme 0.002
0.19
5 years 0
Extreme 0.002
0.44
10 years 0
Extreme 0.002
4.55
Manager TitleAgeSince
Director of Finance/CFO - 2024-08-13
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer - 2017-12-31
Director TitleAgeSince
Chairman 79 2025-02-09
Director/Board Member 59 2025-03-30
Chairman - 2025-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
6/12/24 Buy

Chief Executive Officer

205,500 0.0469%
8/1/23 Buy

Director

165,515 0.0341%
8/1/23 Buy

Chairman

284,091 0.0585%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-50.00%-95.83% 5.95M
+0.52%-1.54%+15.00%+171.23% 350M
0.00%-7.55%-35.81%-41.90% 150M
+1.28%-0.50%+15.12%+102.04% 140M
+6.59%+4.30%-29.71%-62.11% 92.49M
-1.41%-0.49%-40.46%-48.25% 62.82M
Average +1.16%-1.08%-20.98%+4.20% 133.42M
Weighted average by Cap. +1.10%-1.70%-4.49%+73.11%

Financials

2024 2025
Net sales 18.36M 13.17M 11.34M 10.74M 9.74M 18.27M 1.26B 128M 49.06M 640M 49.45M 48.36M 2.02B 13.25M 9.51M 8.19M 7.75M 7.03M 13.19M 908M 92.1M 35.42M 462M 35.7M 34.91M 1.46B
Net income -51.24M -36.75M -31.66M -29.98M -27.18M -50.98M -3.51B -356M -137M -1.79B -138M -135M -5.64B -22.34M -16.03M -13.81M -13.07M -11.85M -22.23M -1.53B -155M -59.71M -779M -60.19M -58.87M -2.46B
Net Debt 70.83M 50.8M 43.77M 41.44M 37.56M 70.47M 4.85B 492M 189M 2.47B 191M 187M 7.8B 75.83M 54.39M 46.86M 44.37M 40.22M 75.45M 5.2B 527M 203M 2.64B 204M 200M 8.35B
Logo Cann Group Limited
Cann Group Limited is an Australia-based company, which is focused on developing, producing, and supplying innovative cannabis medicines. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the Company, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. It operates through cultivation of the medicinal cannabis segment. The Company supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. It also owns Satipharm and its patent-protected capsule technology. The Company's research and good manufacturing practices (GMP) manufacturing facilities are near Mildura, Victoria.
Employees
-
Date Price Change Volume
26-09-11 A$0.005000 0.00% 1,209,242
26-09-10 A$0.005000 0.00% 2,396,802
26-09-09 A$0.005000 0.00% 470,664
26-09-08 A$0.005000 0.00% 2,179,054
26-09-07 A$0.005000 0.00% 1,777,071
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!